Embecta (EMBC) Competitors

$3.90 -5.35 (-57.84%)

Closing price 04:00 PM Eastern

Extended Trading

$4.02 +0.12 (+3.18%)

As of 07:59 PM Eastern

EMBC vs. EYE, ESTA, AORT, INSP, and PLSE

Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include National Vision (EYE), Establishment Labs (ESTA), Artivion (AORT), Inspire Medical Systems (INSP), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry.

How does Embecta compare to National Vision?

Embecta (NASDAQ:EMBC) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

: In the previous week, Embecta had 8 more articles in the media than National Vision. MarketBeat recorded 12 mentions for Embecta and 4 mentions for National Vision. National Vision's average media sentiment score of 1.24 beat Embecta's score of 0.70 indicating that National Vision is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Embecta
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
National Vision
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Embecta has a net margin of 12.92% compared to National Vision's net margin of 1.49%. National Vision's return on equity of 5.15% beat Embecta's return on equity.
Company Net Margins Return on Equity Return on Assets
Embecta 12.92% -26.66% 16.06%
National Vision 1.49% 5.15% 2.22%
: Embecta has higher earnings, but lower revenue than National Vision. Embecta is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Embecta $1.08B 0.21 $95.40M $2.37 1.65
National Vision $1.99B 0.90 $29.60M $0.37 60.65
: Embecta has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
: Embecta presently has a consensus target price of $18.50, suggesting a potential upside of 374.36%. National Vision has a consensus target price of $31.21, suggesting a potential upside of 39.10%. Given Embecta's higher possible upside, analysts plainly believe Embecta is more favorable than National Vision.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Embecta
0 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
National Vision
0 Sell rating(s)

6 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.57
: 93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 2.7% of National Vision shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
National Vision	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Embecta	12.92%	-26.66%	16.06%
National Vision	1.49%	5.15%	2.22%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.21	$95.40M	$2.37	1.65
National Vision	$1.99B	0.90	$29.60M	$0.37	60.65

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
National Vision	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

National Vision beats Embecta on 9 of the 16 factors compared between the two stocks.

How does Embecta compare to Establishment Labs?

Embecta (NASDAQ:EMBC) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

: In the previous week, Establishment Labs had 2 more articles in the media than Embecta. MarketBeat recorded 14 mentions for Establishment Labs and 12 mentions for Embecta. Embecta's average media sentiment score of 0.70 beat Establishment Labs' score of 0.41 indicating that Embecta is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Embecta
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Establishment Labs
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Embecta has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
: Embecta has a net margin of 12.92% compared to Establishment Labs' net margin of -24.19%. Embecta's return on equity of -26.66% beat Establishment Labs' return on equity.
Company Net Margins Return on Equity Return on Assets
Embecta 12.92% -26.66% 16.06%
Establishment Labs -24.19% -201.79% -15.03%
: Embecta has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Embecta $1.08B 0.21 $95.40M $2.37 1.65
Establishment Labs $211.08M 9.88 -$51.06M -$1.74 N/A
: 93.8% of Embecta shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Embecta presently has a consensus target price of $18.50, suggesting a potential upside of 374.36%. Establishment Labs has a consensus target price of $86.86, suggesting a potential upside of 22.35%. Given Embecta's higher probable upside, equities research analysts clearly believe Embecta is more favorable than Establishment Labs.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Embecta
0 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Establishment Labs
1 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Establishment Labs	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Embecta	12.92%	-26.66%	16.06%
Establishment Labs	-24.19%	-201.79%	-15.03%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.21	$95.40M	$2.37	1.65
Establishment Labs	$211.08M	9.88	-$51.06M	-$1.74	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Embecta beats Establishment Labs on 9 of the 15 factors compared between the two stocks.

How does Embecta compare to Artivion?

Embecta (NASDAQ:EMBC) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

: Embecta has a net margin of 12.92% compared to Artivion's net margin of 2.21%. Artivion's return on equity of 7.43% beat Embecta's return on equity.
Company Net Margins Return on Equity Return on Assets
Embecta 12.92% -26.66% 16.06%
Artivion 2.21% 7.43% 3.53%
: Embecta has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.
: 93.8% of Embecta shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 6.3% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Embecta currently has a consensus target price of $18.50, suggesting a potential upside of 374.36%. Artivion has a consensus target price of $51.00, suggesting a potential upside of 41.89%. Given Embecta's higher probable upside, research analysts clearly believe Embecta is more favorable than Artivion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Embecta
0 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Artivion
0 Sell rating(s)

1 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.88
: Embecta has higher revenue and earnings than Artivion. Embecta is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Embecta $1.08B 0.21 $95.40M $2.37 1.65
Artivion $441.33M 3.95 $9.77M $0.20 179.72
: In the previous week, Embecta had 9 more articles in the media than Artivion. MarketBeat recorded 12 mentions for Embecta and 3 mentions for Artivion. Embecta's average media sentiment score of 0.70 beat Artivion's score of 0.61 indicating that Embecta is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Embecta
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Artivion
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Net Margins	Return on Equity	Return on Assets
Embecta	12.92%	-26.66%	16.06%
Artivion	2.21%	7.43%	3.53%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Artivion	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.21	$95.40M	$2.37	1.65
Artivion	$441.33M	3.95	$9.77M	$0.20	179.72

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Artivion	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Embecta beats Artivion on 9 of the 16 factors compared between the two stocks.

How does Embecta compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

: Inspire Medical Systems has higher earnings, but lower revenue than Embecta. Embecta is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inspire Medical Systems $911.98M 1.52 $145.42M $4.98 9.69
Embecta $1.08B 0.21 $95.40M $2.37 1.65
: Inspire Medical Systems presently has a consensus target price of $85.00, suggesting a potential upside of 76.21%. Embecta has a consensus target price of $18.50, suggesting a potential upside of 374.36%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than Inspire Medical Systems.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inspire Medical Systems
1 Sell rating(s)
15 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.15
Embecta
0 Sell rating(s)

4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Inspire Medical Systems had 18 more articles in the media than Embecta. MarketBeat recorded 30 mentions for Inspire Medical Systems and 12 mentions for Embecta. Inspire Medical Systems' average media sentiment score of 0.94 beat Embecta's score of 0.70 indicating that Inspire Medical Systems is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inspire Medical Systems
14 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Embecta
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
: Inspire Medical Systems has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
: 94.9% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 2.2% of Inspire Medical Systems shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Inspire Medical Systems has a net margin of 14.33% compared to Embecta's net margin of 12.92%. Inspire Medical Systems' return on equity of 10.66% beat Embecta's return on equity.
Company Net Margins Return on Equity Return on Assets
Inspire Medical Systems 14.33% 10.66% 9.00%
Embecta 12.92% -26.66% 16.06%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	1.52	$145.42M	$4.98	9.69
Embecta	$1.08B	0.21	$95.40M	$2.37	1.65

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Embecta	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	14 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	14.33%	10.66%	9.00%
Embecta	12.92%	-26.66%	16.06%

Summary

Inspire Medical Systems beats Embecta on 12 of the 16 factors compared between the two stocks.

How does Embecta compare to Pulse Biosciences?

Embecta (NASDAQ:EMBC) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

: Embecta has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Embecta $1.08B 0.21 $95.40M $2.37 1.65
Pulse Biosciences $350K 3,635.15 -$72.78M -$1.08 N/A
: Embecta presently has a consensus target price of $18.50, suggesting a potential upside of 374.36%. Pulse Biosciences has a consensus target price of $30.00, suggesting a potential upside of 60.86%. Given Embecta's higher probable upside, equities analysts plainly believe Embecta is more favorable than Pulse Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Embecta
0 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Pulse Biosciences
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: In the previous week, Embecta had 6 more articles in the media than Pulse Biosciences. MarketBeat recorded 12 mentions for Embecta and 6 mentions for Pulse Biosciences. Embecta's average media sentiment score of 0.70 beat Pulse Biosciences' score of 0.47 indicating that Embecta is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Embecta
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Pulse Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Embecta has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
: 93.8% of Embecta shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Comparatively, 74.6% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Embecta has a net margin of 12.92% compared to Pulse Biosciences' net margin of 0.00%. Embecta's return on equity of -26.66% beat Pulse Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Embecta 12.92% -26.66% 16.06%
Pulse Biosciences N/A -80.51% -69.14%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.21	$95.40M	$2.37	1.65
Pulse Biosciences	$350K	3,635.15	-$72.78M	-$1.08	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Pulse Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Embecta	12.92%	-26.66%	16.06%
Pulse Biosciences	N/A	-80.51%	-69.14%

Summary

Embecta beats Pulse Biosciences on 10 of the 15 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EMBC vs. The Competition

Export

Metric	Embecta	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$547.78M	$8.11B	$6.24B	$11.86B
Dividend Yield	6.49%	2.18%	2.73%	5.21%
P/E Ratio	3.05	24.84	29.04	28.48
Price / Sales	0.21	17.51	477.10	60.43
Price / Cash	2.31	13.23	27.62	36.52
Price / Book	-0.35	4.94	9.67	6.67
Net Income	$95.40M	$183.43M	$3.55B	$332.64M
7 Day Performance	-56.81%	0.20%	1.70%	2.01%
1 Month Performance	-55.93%	5.27%	5.62%	9.19%
1 Year Performance	-68.70%	0.38%	34.42%	39.59%

Embecta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EMBC Embecta	3.9291 of 5 stars	$3.90 -57.8%	$18.50 +374.4%	N/A	$547.78M	$1.08B	3.05	1,850	News Coverage Earnings Report Dividend Cut Analyst Downgrade Gap Down High Trading Volume
EYE National Vision	3.756 of 5 stars	$25.30 +2.2%	$31.21 +23.4%	N/A	$2.01B	$1.99B	68.31	13,138	Positive News
ESTA Establishment Labs	3.1391 of 5 stars	$64.86 -0.9%	$86.86 +33.9%	N/A	$1.91B	$211.08M	N/A	1,004	News Coverage Upcoming Earnings Insider Trade
AORT Artivion	4.0237 of 5 stars	$36.88 -0.4%	$51.00 +38.3%	N/A	$1.78B	$441.33M	183.91	1,800	Upcoming Earnings
INSP Inspire Medical Systems	4.687 of 5 stars	$55.56 +0.9%	$101.41 +82.5%	N/A	$1.60B	$911.98M	11.15	1,333	Trending News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EMBC) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Embecta (EMBC) Competitors

EMBC vs. EYE, ESTA, AORT, INSP, and PLSE

How does Embecta compare to National Vision?

Summary

How does Embecta compare to Establishment Labs?

Summary

How does Embecta compare to Artivion?

Summary

How does Embecta compare to Inspire Medical Systems?

Summary

How does Embecta compare to Pulse Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EMBC vs. The Competition

Embecta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Embecta (EMBC) Competitors

EMBC vs. EYE, ESTA, AORT, INSP, and PLSE

How does Embecta compare to National Vision?

Summary

How does Embecta compare to Establishment Labs?

Summary

How does Embecta compare to Artivion?

Summary

How does Embecta compare to Inspire Medical Systems?

Summary

How does Embecta compare to Pulse Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EMBC vs. The Competition

Embecta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools